tbuckley/cabot-search huggingface dataset:
Effect of Alirocumab on Carotid Inflammation by [18F]FDG PET in Patients With Acute Myocardial Infarction
Authors: Lia E. Bang, Jacob Kildevang Jensen, Lorenz Räber, Konstantinos C. Koskinas, Sarah Bär, Sylvain Losdat, Christian M. Matter, Jacob Lonborg, Maria D. Radu Juul Jensen, Andreas Kjaer, Thomas Engstrøm, Rasmus Sejersten Ripa
Journal: JACC. Cardiovascular imaging (2024)
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study
Authors: Keila Mitsunaga, Martine Bagot, Caroline Ram-Wolff, Emmanuella Guenova, Christina von Gugelberg, Emmilia Hodak, Iris Amitay-Laish, Evangelia Papadavid, Constanze Jonak, Stefanie Porkert, Julia Scarisbrick, Rona Applewaite, Marie Beylot-Barry, Jan Nicolay, Pietro Quaglino, José Antonio Sanches, Jade Cury-Martins, David Lora-Pablos, Pablo Ortiz
Journal: British Journal of Dermatology (2024)

Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon (IFN)-α (subtypes 2a and 2b) has been used to treat MF/SS since 1984; however, its production was recently stopped. The recombinant pegylated (PEG) form of IFN-α-2a remains the only alternative IFN treatment, although it has not been approved for use in MF/SS.
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Authors: Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Journal: Liver Cancer (2024)

The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD-1/PD-L1 blockers. As a results, it is not clear whether the first-line systemic treatment atezolizumab plus bevacizumab (A + B) is equally effective in viral and nonviral patients.
Metastatic Lung Adenocarcinoma Received Combined 177Lu-FAP-2286 Radiation Therapy and Targeted Therapy
Authors: Hongyu Yang, Huipan Liu, Yu Zhang, Yu Zhang, Yue Chen
Journal: Clinical Nuclear Medicine (2024)

Abstract A 56-year-old man with metastatic lung adenocarcinoma received combined 177 Lu-FAP-2286 radiation therapy and targeted therapy. After 1 treatment cycle, improvement of symptoms and radiological remission was observed. Moreover, the patient did not report any adverse effects.
18F-FDG PET/CT in Solitary Extramedullary Plasmacytoma of the Penis
Authors: Xueqi Chen, Guoqian Chen, Qian Li, Zhanli Fu
Journal: Clinical Nuclear Medicine (2024)

A 72-year-old man presented with a painless penile mass for 3 months. Contrast-enhanced CT revealed heterogeneous enhancement, whereas 18 F-FDG PET/CT displayed inhomogeneous 18 F-FDG accumulation in the lesion without other abnormal activity. The histopathological examination from biopsied specimen confirmed the diagnosis of a plasmacytoma. However, the subsequent tests, including serum/urine immunofixation electrophoresis, serum/urine free light chain assay, and bone marrow smear/biopsy, did not show any abnormalities. The conclusive diagnosis was a solitary extramedullary plasmacytoma of the penis.
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance
Authors: Arnau Llinas-Bertran, Meritxell Bellet-Ezquerra, Jose A. Seoane
Journal: Cancer Discovery (2024)

Summary: Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al., p. 866 (9).
Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis
Authors: Zilong Bai, Nicholas Bartelo, Maryam Aslam, Elisabeth A. Murphy, Caryn R. Hale, Nathalie E. Blachere, Salina Parveen, Edoardo Spolaore, Edward DiCarlo, Ellen M. Gravallese, Melanie H. Smith, Mayu O. Frank, Caroline S. Jiang, Haotan Zhang, Christina Pyrgaki, Myles J. Lewis, Shafaq Sikandar, Costantino Pitzalis, Joseph B. Lesnak, Khadijah Mazhar, Theodore J. Price, Anne-Marie Malfait, Rachel E. Miller, Fan Zhang, Susan Goodman, Robert B. Darnell, Fei Wang, Dana E. Orange, Jennifer Albrecht, Jennifer H. Anolik, William Apruzzese, Brendan F. Boyce, David L. Boyle, Michael B. Brenner, S. Louis Bridges, Christopher D. Buckley, Jane H. Buckner, Vivian P. Bykerk, James Dolan, Laura T. Donlin, Andrew Filer, Gary S. Firestein, Chamith Y. Fonseka, Peter K. Gregersen, Joel M. Guthridge, Maria Gutierrez-Arcelus, V. Michael Holers, Laura B. Hughes, Lionel B. Ivashkiv, Eddie A. James, Judith A. James, A. Helena Jonsson, Stephen Kelly, James A. Lederer, Yvonne C. Lee, Arthur M. Mandelin, Mandy J. McGeachy, Joseph R. Mears, Nida Meednu, Larry Moreland, Harris Perlman, Javier Rangel-Moreno, Deepak A. Rao, Soumya Raychaudhuri, Christopher Ritchlin, William H. Robinson, Mina Rohani-Pichavant, Jennifer Seifert, Kamil Slowikowski, Darren Tabechian, Paul J. Utz, Gerald F. M. Watts, Kevin Wei
Journal: Science Translational Medicine (2024)

It has been presumed that rheumatoid arthritis (RA) joint pain is related to inflammation in the synovium; however, recent studies reveal that pain scores in patients do not correlate with synovial inflammation. We developed a machine-learning approach (graph-based gene expression module identification or GbGMI) to identify an 815-gene expression module associated with pain in synovial biopsy samples from patients with established RA who had limited synovial inflammation at arthroplasty. We then validated this finding in an independent cohort of synovial biopsy samples from patients who had early untreated RA with little inflammation. Single-cell RNA sequencing analyses indicated that most of these 815 genes were most robustly expressed by lining layer synovial fibroblasts. Receptor-ligand interaction analysis predicted cross-talk between human lining layer fibroblasts and human dorsal root ganglion neurons expressing calcitonin gene–related peptide (CGRP + ). Both RA synovial fibroblast culture supernatant and netrin-4, which is abundantly expressed by lining fibroblasts and was within the GbGMI-identified pain-associated gene module, increased the branching of pain-sensitive murine CGRP + dorsal root ganglion neurons in vitro. Imaging of solvent-cleared synovial tissue with little inflammation from humans with RA revealed CGRP + pain-sensing neurons encasing blood vessels growing into synovial hypertrophic papilla. Together, these findings support a model whereby synovial lining fibroblasts express genes associated with pain that enhance the growth of pain-sensing neurons into regions of synovial hypertrophy in RA.
Gastric Fundus Splenosis Mimicking Malignancy on FDG PET/CT
Authors: Linlin Guo, Guohua Shen
Journal: Clinical Nuclear Medicine (2024)

A 17-year-old man presented with dull pain in the left upper abdomen for 1 month. Initial CT and gastroscopy revealed a mass in the gastric fundas, protruding into the lumen. Based on findings of a fine-needle biopsy, an inflammatory myofibroblastic tumor was suspected. Subsequent PET/CT showed increased FDG uptake in the gastric fundas as well as hepatogastric ligament, para-aortic region. Eventually, he underwent surgical resection, and histopathologic findings confirmed the diagnosis of splenosis.
Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma
Authors: Kimberly Nellenbach, Emily Mihalko, Seema Nandi, Drew W. Koch, Jagathpala Shetty, Leandro Moretti, Jennifer Sollinger, Nina Moiseiwitsch, Ana Sheridan, Sanika Pandit, Maureane Hoffman, Lauren V. Schnabel, L. Andrew Lyon, Thomas H. Barker, Ashley C. Brown
Journal: Science Translational Medicine (2024)

Uncontrolled bleeding after trauma represents a substantial clinical problem. The current standard of care to treat bleeding after trauma is transfusion of blood products including platelets; however, donated platelets have a short shelf life, are in limited supply, and carry immunogenicity and contamination risks. Consequently, there is a critical need to develop hemostatic platelet alternatives. To this end, we developed synthetic platelet-like particles (PLPs), formulated by functionalizing highly deformable microgel particles composed of ultralow cross-linked poly ( N -isopropylacrylamide) with fibrin-binding ligands. The fibrin-binding ligand was designed to target to wound sites, and the cross-linking of fibrin polymers was designed to enhance clot formation. The ultralow cross-linking of the microgels allows the particles to undergo large shape changes that mimic platelet shape change after activation; when coupled to fibrin-binding ligands, this shape change facilitates clot retraction, which in turn can enhance clot stability and contribute to healing. Given these features, we hypothesized that synthetic PLPs could enhance clotting in trauma models and promote healing after clotting. We first assessed PLP activity in vitro and found that PLPs selectively bound fibrin and enhanced clot formation. In murine and porcine models of traumatic injury, PLPs reduced bleeding and facilitated healing of injured tissue in both prophylactic and immediate treatment settings. We determined through biodistribution experiments that PLPs were renally cleared, possibly enabled by ultrasoft particle properties. The performance of synthetic PLPs in the preclinical studies shown here supports future translational investigation of these hemostatic therapeutics in a trauma setting.
68Ga-FAPI-04 PET/CT Imaging of Mesenteric Aggressive Fibromatosis
Authors: Jing Wei, Xiaoliang Chen
Journal: Clinical Nuclear Medicine (2024)

Aggressive fibromatosis is a relatively rare disease. We describe 68 Ga-FAPI-04 PET/CT findings in a case of histologically proved mesenteric aggressive fibromatosis. 68 Ga-FAPI-04 PET/CT revealed a mass in the mesentery with increased FAPI activity. This case indicates that FAPI PET may be useful for evaluation of aggressive fibromatosis.
Splenic Pseudoprogression After CAR-T Therapy Detected by 18F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient
Authors: Xilan Yao, Hongrong Wang, Ying Kan, Wei Wang, Jigang Yang
Journal: Clinical Nuclear Medicine (2024)

A 43-year-old woman diagnosed with refractory diffuse large B-cell lymphoma was referred to chimeric antigen receptor T-cell therapy at our institution. After 3 cycles of bridging therapy, preinfusion 18 F-FDG PET/CT suggested a complete metabolic response. 18 F-FDG PET/CT 1 month after chimeric antigen receptor T-cell infusion showed 2 foci of elevated activity in the spleen, which was finally confirmed as pseudoprogression.
Prostate-Specific Membrane Antigen–Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18F-PSMA-1007 PET/CT
Authors: Piyush Aggarwal, Nivetha Ambalavanan, Ashwani Sood, Kirti Gupta, Divya Dahiya, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2024)

Abstract The occurrence of cutaneous metastases in prostate cancer is exceedingly rare. Many benign lesions and nonprostatic cancers can express the prostate-specific membrane antigen (PSMA). They can potentially mimic metastasis of prostate cancer and lead to misinterpretation of PSMA PET/CT findings. Additionally, it has significant management and prognostic implications. We present a rare case of an 88-year-old man with metastatic castration-resistant prostate cancer who showed a PSMA-expressing subcutaneous nodule in the scalp on 18 F-PSMA-1007 PET/CT, raising the suspicion of cutaneous metastasis. However, its biopsy revealed a neurofibroma, altering the disease prognosis and management.
A mouse model of chronic primary pain that integrates clinically relevant genetic vulnerability, stress, and minor injury
Authors: Yaomin Wang, Shin Hyung Kim, Marguerita E. Klein, Jiegen Chen, Elizabeth Gu, Shad Smith, Andrey Bortsov, Gary D. Slade, Xin Zhang, Andrea G. Nackley
Journal: Science Translational Medicine (2024)

Chronic primary pain conditions (CPPCs) affect over 100 million Americans, predominantly women. They remain ineffectively treated, in large part because of a lack of valid animal models with translational relevance. Here, we characterized a CPPC mouse model that integrated clinically relevant genetic (catechol-O-methyltransferase; COMT knockdown) and environmental (stress and injury) factors. Compared with wild-type mice,
Contribution of the patient microbiome to surgical site infection and antibiotic prophylaxis failure in spine surgery
Authors: Dustin R. Long, Chloe Bryson-Cahn, Adam Waalkes, Elizabeth A. Holmes, Kelsi Penewit, Celeste Tavolaro, Carlo Bellabarba, Fangyi Zhang, Jeannie D. Chan, Ferric C. Fang, John B. Lynch, Stephen J. Salipante
Journal: Science Translational Medicine (2024)

Despite modern antiseptic techniques, surgical site infection (SSI) remains a leading complication of surgery. However, the origins of SSI and the high rates of antimicrobial resistance observed in these infections are poorly understood. Using instrumented spine surgery as a model of clean (class I) skin incision, we prospectively sampled preoperative microbiomes and postoperative SSI isolates in a cohort of 204 patients. Combining multiple forms of genomic analysis, we correlated the identity, anatomic distribution, and antimicrobial resistance profiles of SSI pathogens with those of preoperative strains obtained from the patient skin microbiome. We found that 86% of SSIs, comprising a broad range of bacterial species, originated endogenously from preoperative strains, with no evidence of common source infection among a superset of 1610 patients. Most SSI isolates (59%) were resistant to the prophylactic antibiotic administered during surgery, and their resistance phenotypes correlated with the patient's preoperative resistome (
BCR signaling is required for posttransplant lymphoproliferative disease in immunodeficient mice receiving human B cells
Authors: Ting-ting Zhang, Rene Yu-Hong Cheng, Andee R. Ott, Noelle P. Dahl, Emmaline R. Suchland, Claire M. Stoffers, Gregory D. Asher, Deyin Hou, Christopher D. Thouvenel, Tyler F. Hill, David J. Rawlings, Richard G. James
Journal: Science Translational Medicine (2024)

Posttransplant lymphoproliferative disease (PTLD) is a major therapeutic challenge that has been difficult to study using human cells because of a lack of suitable models for mechanistic characterization. Here, we show that ex vivo-differentiated B cells isolated from a subset of healthy donors can elicit pathologies similar to PTLD when transferred into immunodeficient mice. The primary driver of PTLD-like pathologies were IgM-producing plasmablasts with Epstein-Barr virus (EBV) genomes that expressed genes commonly associated with EBV latency. We show that a small subset of EBV
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Authors: Harry Fruchtman, Zachary M. Avigan, Julian A. Waksal, Nicole Brennan, John O. Mascarenhas
Journal: Leukemia (2024)

The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has broadened our understanding of the heterogeneous molecular basis of the disease. Since genetic sequencing has become a standard practice, several driver mutations have been identified. Accordingly, novel targeted therapeutic agents have been developed and are now approved for the treatment of subsets of patients that carry mutations in FLT3, IDH1, and IDH2 [1, 2]. The emergence of these novel agents in AML offers patients a new modality of therapy, and shifts treatment paradigms toward individualized medicine. In this review, we outline the role of IDH mutations in malignant transformation, focus in on a novel group of targeted therapeutic agents directed toward IDH1- and IDH2-mutant AML, and explore their impact on prognosis in patients with AML.
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
Authors: Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà, Michael Weller, Susan M Chang, Martin J van den Bent, Patrick Y Wen, Riccardo Soffietti
Journal: Neuro-Oncology (2024)

The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors.
Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor
Authors: Fariba Tohidinezhad, Catharina M L Zegers, Femke Vaassen, Jeanette Dijkstra, Monique Anten, Wouter Van Elmpt, Dirk De Ruysscher, Andre Dekker, Daniëlle B P Eekers, Alberto Traverso
Journal: Neuro-Oncology (2024)

Abstract Background Deterioration of neurocognitive function in adult patients with a primary brain tumor is the most concerning side effect of radiotherapy. This study aimed to develop and evaluate normal-tissue complication probability (NTCP) models using clinical and dose–volume measures for 6-month, 1-year, and 2-year Neurocognitive Decline (ND) postradiotherapy. Methods A total of 219 patients with a primary brain tumor treated with radical photon and/or proton radiotherapy (RT) between 2019 and 2022 were included. Controlled oral word association test, Hopkins verbal learning test-revised, and trail making test were used to objectively measure ND. A comprehensive set of potential clinical and dose–volume measures on several brain structures were considered for statistical modeling. Clinical, dose–volume and combined models were constructed and internally tested in terms of discrimination (area under the curve, AUC), calibration (mean absolute error, MAE), and net benefit. Results Fifty percent, 44.5%, and 42.7% of the patients developed ND at 6-month, 1-year, and 2-year time points, respectively. The following predictors were included in the combined model for 6-month ND: age at radiotherapy &amp;gt; 56 years (OR = 5.71), overweight (OR = 0.49), obesity (OR = 0.35), chemotherapy (OR = 2.23), brain V20 Gy ≥ 20% (OR = 3.53), brainstem volume ≥ 26 cc (OR = 0.39), and hypothalamus volume ≥ 0.5 cc (OR = 0.4). Decision curve analysis showed that the combined models had the highest net benefits at 6-month (AUC = 0.79, MAE = 0.021), 1-year (AUC = 0.72, MAE = 0.027), and 2-year (AUC = 0.69, MAE = 0.038) time points. Conclusions The proposed NTCP models use easy-to-obtain predictors to identify patients at high risk of ND after brain RT. These models can potentially provide a base for RT-related decisions and post-therapy neurocognitive rehabilitation interventions.
An injectable thermoresponsive-hydrogel for lamellar keratoplasty: In-situ releases celastrol and hampers corneal scars
Authors: Zhanrong Li, Ruixing Liu, Xiacong Zhang, Zhihua Guo, Xingchen Geng, Dandan Chu, Haohao Cui, Afang Zhang, Wen Li, Lei Zhu, Jingguo Li
Journal: Journal of Controlled Release (2024)
Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
Authors: Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, M. Rita Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andres Cardona, Thorsten Ruf, Johannes Noe, Benjamin J. Solomon
Journal: New England Journal of Medicine (2024)

Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable,
Requiem for Urate Lowering in CKD?
Authors: David B. Mount
Journal: Journal of the American Society of Nephrology (2024)

Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, and Renal Division, VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts Correspondence: Dr. David B. Mount, email: [email protected] See related article, "Combination Treatment with Verinurad and Allopurinol in CKD: a Randomized Placebo and Active Controlled Trial," on pages 594–606.
Public Reporting of Heart Transplant Center Performance
Authors: Shahnawaz Amdani, Elizabeth N. Dewey, Jesse D. Schold
Journal: JACC Heart Failure (2024)

Transplant center report cards are publicly available and used by regulators, insurance payers, and importantly patients and families. In this study, the authors sought to evaluate the variability in reported public performance ratings of pediatric and adult heart transplant centers. Program-specific reports from the Scientific Registry of Transplant Recipients from 2017-2021 were used to evaluate stability, volatility, and reliability of 3 publicly reported ratings: waitlist survival (WS), getting to a faster transplant (FT), and post-transplantation graft failure (GF). There were 112 adult and 55 pediatric centers. Over the study period, nearly all centers (98%) had at least 1 change in rating in at least 1 of the tiers. The average time to the first rating change of any magnitude was 12-18 months for all tiers and centers. For adult centers, the most volatile rating was WS (SD: 0.77), followed by GF (SD: 0.76) and then FT (SD: 0.57). For pediatric centers, the most volatile rating was WS (SD: 0.79), followed by both GF (SD: 0.66) and FT (SD: 0.68), which were equally volatile. All tiers except adult FT had an estimated Fleiss's kappa <0.20, indicating poor agreement/consistency across the study period. In addition, the intraclass correlation coefficient for all tiers was <0.50, indicating poor reliability. The current 5-tier reporting of transplant center performance is highly volatile and has poor reliability and consistency. Given the unintended and significant negative consequences these reports can have, critical revision of these ratings is warranted.
Detection of Adenocarcinoma of the Colon on 18F-Fluciclovine PET/CT
Authors: Charisma Desai, Angela Clark, Devaki Shilpa Surasi, Lesley Flynt
Journal: Clinical Nuclear Medicine (2024)

An 85-year-old man with prostate cancer and de novo bone metastases was treated with hormonal therapy with resolution of bone lesions, improved primary disease, and improved serum tumor markers. Although on hormonal therapy, biochemical recurrence prompted performance of 18 F-fluciclovine PET/CT. Fluciclovine PET/CT revealed primary prostate cancer progression with incidental note of avid foci in the colon for which colonoscopy was recommended. Colonoscopy with biopsy was performed with pathology revealing primary colon adenocarcinoma. Before reinitiation of prostate cancer therapy, segmental colon resection was performed with pathology positive for additional sites of colon cancer.